SCHEMBL735832

SCHEMBL735832

O=C(O)CCc1ccc[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.53
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 1/20 0.49
HSD17B10 Q99714 1/20 0.49
KEAP1 Q14145 1/20 0.48
FFAR1 O14842 3/20 0.45
PARP1 P09874 1/20 0.44
CHRM1 P11229 1/20 0.42
HDAC3 O15379 1/20 0.41
MAPK1 P28482 1/20 0.41
ADRA1A P35348 1/20 0.41
HDAC4 P56524 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HDAC1 Q13547 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Monoethanolamine SCHEMBL18979870 0.89 TSHR (0.45) TSHRCYP1A2CYP2C9HSD17B10KEAP1
SCHEMBL736098 0.88 HDAC3 (0.52) TSHRCYP1A2HSD17B10KEAP1FFAR1
SCHEMBL27608146 0.86 MAPT (0.52) TSHRHDAC3MAPK1ADRA1AHDAC4
SCHEMBL2932213 0.85 MAPT (0.55) TSHRHDAC3MAPK1ADRA1AHDAC4
SCHEMBL30661655 0.85 MAPT (0.55) TSHRHDAC3MAPK1ADRA1AHDAC4
SCHEMBL736113 0.85 MAPT (0.55) TSHRHDAC3MAPK1ADRA1AHDAC4
SCHEMBL1471746 0.85 MAPT (0.55) TSHRHDAC3MAPK1ADRA1AHDAC4
SCHEMBL9680709 0.83 MAPT (0.45) TSHRCYP1A2CYP2C9HSD17B10HDAC3
SCHEMBL10362176 0.82 ALDH1A1 (0.48) TSHRSMN1; SMN2ALDH1A1
SCHEMBL7130655 0.82 CAPN1 (0.47) TSHRNAPRT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615559-B1 MODIFIED COMPLEMENT PROTEINS AND USES THEREOF UNIV NEWCASTLE (GB) 2025-06-18 EP claimed
CN-119816735-A Methods and assays for secretory proteome activity analysis 康巴乔有限公司 2025-04-11 CN claimed
US-20240376172-A1 INTERLEUKIN 2 CHIMERIC CONSTRUCTS WITH TARGETING SPECIFICY TO INFLAMED TISSUES ILTOO PHARMA (FR) 2024-11-14 US claimed
CN-118829420-A Multivesicular lipid nanoparticle-tolerant vaccine for inducing systemic immune tolerance in vivo 卡尔马ABC有限责任公司 2024-10-22 CN claimed
US-20240012011-A1 METHODS AND ASSAYS FOR SECRETOME ACTIVITY ANALYSIS OXFORD FINANCE LLC 2024-01-11 US claimed
CN-116036084-A Application of stephanine in preparing medicine for treating coronavirus infection patient 上海甘合商务信息咨询有限公司 2023-05-02 CN claimed
CN-115954111-A Method for searching clinical value target and analytic action mechanism of cepharanthine for treating EBV (Epstein Barr Virus) related tumors 杨江平 2023-04-11 CN claimed
CN-115916174-A Compositions and methods for preventing stress-induced phobia, depression-like, and anxiety-like behaviors 纽约市哥伦比亚大学理事会 2023-04-04 CN claimed
CN-115245804-A Device and process for improving reaction rate of azolepropanoic acid 甘肃联凯生物科技有限公司 2022-10-28 CN claimed
CN-115057829-A Synthesis method of high-purity azolepropanoic acid 甘肃联凯生物科技有限公司 2022-09-16 CN claimed
US-20090155243-A1 NON-HUMAN MODEL OF AUTOIMMUNE DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2009-06-18 US claimed
EP-2049156-A2 COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION The Cleveland Clinic Foundation (US) 2009-04-22 EP claimed
WO-2008089485-A2 CARBOXYETHYLPYRROLE COMPOUNDS AND METHODS OF THEIR PRODUCTION THE CLEVELAND CLINIC FOUNDATION (US) 2008-07-24 WO claimed
US-20080160505-A1 DIAGNOSTIC METHODS FOR AGE RELATED MACULAR DEGENERATION THE CLEVELAND CLINIC FOUNDATION 2008-07-03 US claimed
US-7341839-B2 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION (US) 2008-03-11 US claimed
WO-2008013797-A2 COMPOSITIONS AND METHODS FOR MACULAR DEGENERATION THE CLEVELAND CLINIC FOUNDATION (US) 2008-01-31 WO claimed
WO-2007127151-A2 NON-HUMAN MODEL OF AUTOIMMUNE DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2007-11-08 WO claimed
US-20070072241-A1 diagnosing age-related macular degeneration comprising determining the level of anti-2-( omega -carboxyethyl) pyrrole (CEP) antibodies in a bodily fluid obtained from the test subject NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-03-29 US claimed
US-7172874-B2 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION (US) 2007-02-06 US claimed
US-20040265924-A1 Diagnostic methods for age related macular degeneration THE CLEVELAND CLINIC FOUNDATION 2004-12-30 US claimed